Toranomon Towers Office, 10F,4-1-28 Toranomon, Minato-ku, Tokyo 105-0001, JapanPhone:+81-3-5472-1578 Fax:+81-3-5472-1488

«Office»HI-DEC 2F6-7-4 Minatojima Minamimachi, Chuo-ku, Kobe-shi, Hyogo 650-0047 JapanPhone:+81-78-303-1380 Fax:+81-78-303-1381

«Inspection Center»HI-DEC 3F6-7-4 Minatojima Minamimachi, Chuo-ku, Kobe-shi, Hyogo 650-0047 Japan

Headquarters

Kobe Clinical Laboratory Center

1 Bridge Plaza 2nd floor, Fort Lee, New Jersey, 07024 USAPhone:+1-201-527-0953

Oncolys USA Inc.

https://www.oncolys.com

Company Name

Established

Capital fund

President & CEO

Business Summary

Our Banks

Listing

Oncolys BioPharma Inc.

March 18, 2004

¥7,089 Million (June 30, 2019)

Yasuo Urata

Research and development of oncolytic viruses, drugs for serious infectious diseases, molecular targeted anti-cancer drugs, and tumor diagnostic agentsConsulting services with regard to the research and development of biotechnology drugs

Sumitomo Mitsui Banking CorporationJapan Finance CorporationMizuho Bank, Ltd.The Bank of Tokyo-Mitsubishi UFJ, Ltd.

Tokyo Stock Exchange Mothers(Securities Code:4588)

Toranomon

Roppongi-itchome

Hotel Okura Main Bldg.

Hotel Okura South Bldg.

TV Tokyo

Shiroyama Garden

Embassy of Sweden

Embassy of Spain

Atago Shrine

ARK hills

Hibiya Line

Exit 4b Kamiyacho Sta. (H05)

Route

1: S

akura

da-d

ori A

ve.

1908/200⑥1704(B)

Company Profile

Access

Company Profile

Iryo Center (Shimin Byoin Mae)

Station

Exit〔2〕

Sannomiya Station

Kobe Airport Station

McDonald’s

ACMEMarkets

1 Bridge Plaza North

Econo Lodge Hud

son

Terr

ace

Hoyt Ave

Merkle St

N Hu

dson

St

Cent

ral R

d

Five Guys Burgers and Fries

Budget Car Rental

Washington Bridge Plaza

Cente

r Ave

Licoin Ave

NJ Tpke(Toll road)

Lem

oine

Ave

Interstate 95 Lower Level

I-95 Lower Level(Toll road)

Powering Future Oncotherapy

Oncolytic Virus Immunotherapy

Antiviral Therapy

Rare Diseases

The mission of Oncolys Biopharma is to help both patients and physicians by contributing to the advancement of medical science through bringing innovation to the existing treatments for cancer and serious infectious diseases, with our virology-based new drug discovery technologies. In addition, our long term target is to tackle the challenges in the field of orphan drugs and to address unmet medical needs for patients with intractable diseases around the world.We believe that the shortest way to complete our mission is to license-out our drug candidates at early development stage, to large pharmaceutical companies which are more advantaged from perspectives of access to resources and wide distribution network. This idea is reflected in our business model.Since Oncolys got listed on Tokyo Stock Exchange in December 2013, we have been privileged to receive countless advices and supports from our stakeholders, from patients and medical doctors to investors and public institutions, which is a tremendous amount of encouragement to keep us move on in our endeavors of new drug development.All of us at Oncolys BioPharma remain focused on achieving our mission to bring innovative drugs for patients suffering from intractable cancer and untreatable rare diseases. We believe that our tireless pursuit for novel drugs and scientific contributions, to pave a pathway to a brighter future of patients in need, can make the world healthier and better.

CEO Message

Oncolys BioPharma Inc.

President & CEO Yasuo Urata

Outline of our pipelines

OBP-801OBP-801 is a histone deacetylase (HDAC) inhibitor that shows anti-tumor properties by normalizing the deformed chromatin structure of cancer cells. Also, by promoting the expression of tumor suppressor gene “p21” within cancer cells, the drug suppresses the growth of cancer cells and induces autophagic cell death. Moreover, OBP-801’s HDAC inhibiting activity is far stronger than existing drugs on the market.

OBP-601(Censavudine)

OBP-601(Censavudine) is a novel nucleotide reverse transcriptase inhibitor (NRTI) for HIV infection that is effective against a wide range of NRTI-resistant viruses. It can be administered once a day and used with existing anti-HIV drug therapies. A key feature of OBP-601 is its low toxicity to mitochondria. Also, OBP-601’s safety profile appears better than existing anti-HIV drugs which cause side effects including nerve damage and abnormal lipid metabolism.

O

O

O

C

HO

HC

N

CH3HN

OBP-601

HIV RNA

HIV infection

reverse transcription

HIV

OBP-601

OBP-301(Telomelysin)

Telomelysin

infection

lysis

viral replication

cancer cells

chromatin structure ofcancer cells

chromatin structure ofnormal cells

O OH

SS

O

OOO

HN

NH

NH

OBP-801

OBP-401/1101TelomeScan is a genetically engineered adenovirus type 5 for detecting tumor cells. TelomeScan has a human telomerase reverse transcriptase (hTERT) promoter sequence in the upstream region of virus E1 gene which is responsible for replication of adenovirus, and a green fluorescent protein (GFP) gene in E3 region under the control by cytomegalovirus promoter. It allows for detecting living circulating tumor cells (CTCs) in blood from cancer patients with high sensitivity and specificity, offering a tool for early detection of cancer, monitoring of therapeutic efficacy and tumor recurrence, and selection of appropriate therapy to patients, without conducting risky biopsies.

GFP (TelomeScan) Bright Field GFP + Bright Field

CTCs in cancer patients’ blood

Lung

Breast

Colorectal

Gastric

Pipelines

OncolyticVirus

CancerDiagnostics

OncolyticVirus

Moleculartarget drug

Antiviraldrug

Target indication Explo-ratory

Pre-clinicalstudy PhaseⅠ PhaseⅡ PhaseⅢ

Pharmaceutical Business

Basic research Clinical study Clinical validationCategory Project Target Indication

Diagnostic Business

Project

Soild Tumor

OBP-801

OBP-601（Censavudine）

OBP-AI-004

Telomelysin or OBP-301 is an oncolytic adenovirus in which gene is modified to be able to selectively replicate in cancer cells by introducing human telomerase reverse transcriptase (hTERT) promotor. Oncolytic adenovirus has much potential for cancer immunotherapy because its viral replication is highly immunogenic, and oncolysis induced by such virus releases tumor epitopes and provides costimulatory danger signals. From the result of phase 1 clinical study in the US, Oncolys obtained promising data showing abscopal effect in melanoma patients after single injection into one single tumor and found that not only increasing infiltration of CD8 and antigen presenting cells but diminishing Treg cells in injected tumor site.

OBP-401/1101

Soild Tumor

Ophthalmic use

HIV

HBV

Esophageal cancer

Gastric/gastroesophagealjunction cancer

HCC

Toranomon Towers Office, 10F,4-1-28 Toranomon, Minato-ku, Tokyo 105-0001, JapanPhone:+81-3-5472-1578 Fax:+81-3-5472-1488

«Office»HI-DEC 2F6-7-4 Minatojima Minamimachi, Chuo-ku, Kobe-shi, Hyogo 650-0047 JapanPhone:+81-78-303-1380 Fax:+81-78-303-1381

«Inspection Center»HI-DEC 3F6-7-4 Minatojima Minamimachi, Chuo-ku, Kobe-shi, Hyogo 650-0047 Japan

Headquarters

Kobe Clinical Laboratory Center

1 Bridge Plaza 2nd floor, Fort Lee, New Jersey, 07024 USAPhone:+1-201-527-0953

Oncolys USA Inc.

https://www.oncolys.com

Company Name

Established

Capital fund

President & CEO

Business Summary

Our Banks

Listing

Oncolys BioPharma Inc.

March 18, 2004

¥7,089 Million (June 30, 2019)

Yasuo Urata

Research and development of oncolytic viruses, drugs for serious infectious diseases, molecular targeted anti-cancer drugs, and tumor diagnostic agentsConsulting services with regard to the research and development of biotechnology drugs

Sumitomo Mitsui Banking CorporationJapan Finance CorporationMizuho Bank, Ltd.The Bank of Tokyo-Mitsubishi UFJ, Ltd.

Tokyo Stock Exchange Mothers(Securities Code:4588)

Toranomon

Roppongi-itchome

Hotel Okura Main Bldg.

Hotel Okura South Bldg.

TV Tokyo

Shiroyama Garden

Embassy of Sweden

Embassy of Spain

Atago Shrine

ARK hills

Hibiya Line

Exit 4b Kamiyacho Sta. (H05)

Route

1: S

akura

da-d

ori A

ve.

1908/200⑥1704(B)

Company Profile

Access

Company Profile

Iryo Center (Shimin Byoin Mae)

Station

Exit〔2〕

Sannomiya Station

Kobe Airport Station

McDonald’s

ACMEMarkets

1 Bridge Plaza North

Econo Lodge Hud

son

Terr

ace

Hoyt Ave

Merkle St

N Hu

dson

St

Cent

ral R

d

Five Guys Burgers and Fries

Budget Car Rental

Washington Bridge Plaza

Cente

r Ave

Licoin Ave

NJ Tpke(Toll road)

Lem

oine

Ave

Interstate 95 Lower Level

I-95 Lower Level(Toll road)

Powering Future Oncotherapy

Oncolytic Virus Immunotherapy

Antiviral Therapy

Rare Diseases